Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases

Abstract Aims Mineralocorticoid receptor antagonists (MRAs) are crucial in managing cardiovascular diseases, with different MRAs demonstrating varying efficacy across diverse disease contexts. This research aims to compare the cardiovascular protective effects of different MRAs across various diseas...

Full description

Bibliographic Details
Published in:	ESC Heart Failure
Main Authors:	Jiao Wang, Meijuan Zheng, Yuchun Yang, Lei Zhang, Muhuyati Wulasihan
Format:	Article
Language:	English
Published:	Wiley 2025-08-01
Subjects:	Cardiovascular MACE Mineralocorticoid receptor antagonist MRA Original research
Online Access:	https://doi.org/10.1002/ehf2.15329

Similar Items

A comprehensive review of finerenone—a third-generation non-steroidal mineralocorticoid receptor antagonist
by: Shuhui Zhai, et al.
Published: (2024-09-01)

Heart failure: the role for mineralocorticoid receptor antagonists
by: Bertram Pitt
Published: (2014-05-01)

Mineralocorticoid receptor overactivation-induced remodeling of obese adipose tissue
by: WEN Runzhi, WANG Li, ZHAO Naiqian
Published: (2025-06-01)

In Silico Investigation of Mineralocorticoid Receptor Antagonists: Insights into Binding Mechanisms and Structural Dynamics
by: Julia J. Liang, et al.
Published: (2025-03-01)

Cardiovascular-Kidney-Metabolic Effects: Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists
by: Biykem Bozkurt, et al.
Published: (2025-07-01)

Paradigm shift on the role of mineralocorticoid receptor antagonists in hypertension therapy
by: S. R. Gilyarevsky, et al.
Published: (2023-10-01)

Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
by: Sofia S. Pereira, et al.
Published: (2021-04-01)

MINERALOCORTICOID RECEPTOR ANTAGONISTS THERAPY IN RESISTANT HYPERTENSION: TIME TO IMPLEMENT NEW GUIDELINES?
by: Giuseppe eMaiolino, et al.
Published: (2015-02-01)

Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta‐Analysis
by: Chien‐Wei Huang, et al.
Published: (2025-02-01)

Aldosterone-Related Cardiovascular Disease and Benefits of Mineralocorticoid Receptor Antagonists in Clinical Practice
by: Maria Alfarano, MD, PhD, et al.
Published: (2025-06-01)

Research progress on the effects of mineralocorticoid receptor on cardiovascular diseases
by: MA Qian-yu, PENG Shi, ZHANG Zhao-yuan, ZHANG Dan, ZHANG Jin
Published: (2022-08-01)

Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis
by: Ahmed Elshahat, et al.
Published: (2024-09-01)

The role of mineralocorticoid receptors hyperactivation in the development of cardiorenal complications in patients with diabetes mellitus, perspective of the selective nonsteroidal mineralocorticoid receptors antagonist’s treatment: A review
by: Irina N. Bobkova
Published: (2023-11-01)

Mineralocorticoid receptor antagonists in the treatment of patients with heart failure after myocardial infarction and those with chronic heart failure
by: S N Tereshchenko, et al.
Published: (2013-12-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
by: Nina Vodošek Hojs, et al.
Published: (2021-06-01)

Steroidal Mineralocorticoid Receptor Antagonist Side Effects and Reasons for Discontinuation: A Patient Survey (RELICS-PS)
by: Richard EL, et al.
Published: (2025-04-01)

Prognostic impact of additional mineralocorticoid receptor antagonists in octogenarian heart failure patients
by: Takuro Abe, et al.
Published: (2020-10-01)

Effectiveness and safety of mineralocorticoid receptor antagonists in heart failure patients with and without diabetes: a systematic review and meta-analysis
by: Arga Setyo Adji, et al.
Published: (2024-11-01)

Mineralocorticoid receptor antagonists: new extended roles in cardio- and nephroprotection
by: A. M. Esayan, et al.
Published: (2018-04-01)

Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment
by: Mohamad El Wardani, et al.
Published: (2023-03-01)

Recent Advances and Perspectives on the Use of Mineralocorticoid Receptor Antagonists for the Treatment of Hypertension and Chronic Kidney Disease: A Review
by: Kisho Miyasako, et al.
Published: (2024-12-01)

Assessment of renal and cardiovascular risks in patients with type 2 diabetes when using non-steroidal mineralocorticoid receptor antagonists
by: V.М. Yerokhovych, et al.
Published: (2023-12-01)

Mineralocorticoid receptor antagonists reduce inflammatory signaling independent of myofiber mineralocorticoid receptor
by: Jeovanna Lowe, et al.
Published: (2025-12-01)

Efficacy and Safety of Low‐Dose Spironolactone in Management of Diabetic Kidney Disease in a Real‐World Setting
by: Manochehr Amini, et al.
Published: (2025-07-01)

Expression of genes encoding mineralocorticoid biosynthetic enzymes and the mineralocorticoid receptor, and levels of mineralocorticoids in the bovine follicle and corpus luteum
by: Memory MUKANGWA, et al.
Published: (2019-12-01)

Endogenous bufadienolides, mineralocorticoid receptor antagonists and fibrosis in chronic kidney disease
by: Mai Rosenberg, et al.
Published: (2024-09-01)

Mineralocorticoid receptor antagonists for chronic heart failure: a meta-analysis focusing on the number needed to treat
by: Chang Geng, et al.
Published: (2023-11-01)

Efficacy and safety of nonsteroidal mineralocorticoid receptor antagonists for renal and cardiovascular outcomes in patients with chronic kidney disease: a meta-analysis of randomized clinical trials
by: Qianlan Chen, et al.
Published: (2024-02-01)

Changes of myocardial fibrosis markers with the use of beta-blockers and mineralocorticoid receptor antagonists in patients with heart failure with mid-range ejection fraction of ischemic origin
by: O. A. Osipova, et al.
Published: (2021-11-01)

Chemokine receptor CXCR7 antagonism ameliorates cardiac and renal fibrosis induced by mineralocorticoid excess
by: Bing H. Wang, et al.
Published: (2024-11-01)

Obesity, aldosterone excess, and mineralocorticoid receptor activation: Parallel or intersected circumstances?
by: Houry Puzantian, et al.
Published: (2024-12-01)

Adrenal venous sampling outcomes with and without mineralocorticoid receptor antagonists in primary aldosteronism
by: Sittikul Thipbumrung, et al.
Published: (2025-07-01)

Efficacy and safety of mineralocorticoid receptor antagonists in kidney transplant patients: an updated meta-analysis of randomized controlled trials
by: Paula Dibo, et al.
Published: (2025-08-01)

Efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a meta-analysis of randomized controlled trials
by: Jinfei Wu, et al.
Published: (2025-09-01)

The Effect of Early Spironolactone Administration on 2-Year Acute Graft Rejection in Cardiac Transplant Patients
by: Dragos-Florin Baba, et al.
Published: (2025-05-01)

Efficacy and Safety of Non-Steroidal Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review Incorporating an Indirect Comparisons Meta-Analysis
by: Xinrui Jiang, et al.
Published: (2022-06-01)

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
by: Ulrich Kintscher, et al.
Published: (2023-06-01)

Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis
by: Yue Zhang, et al.
Published: (2025-09-01)

Clinical application of mineralocorticoid receptor antagonists in chronic heart failure
by: MG Bubnova
Published: (2014-12-01)

FIDELIO study: significance and place of finerenone as nonsteroidal mineralocorticoid receptor antagonist in therapy of patients with chronic kidney disease in type 2 diabetes
by: M. S. Shamkhalova, et al.
Published: (2023-12-01)